Do The IMPROVE-IT Results Offer Promise For Anacetrapib, Another Merck Heart Drug?
Despite the fact that anacetrapib lowers LDL at least as well as Vytorin did in IMPROVE-IT, the FDA would never approve anacetrapib based solely on LDL lowering. This is a new experimental agent and the results of REVEAL are needed before the FDA can act. This is not an unreasonable position. It will be interesting to see how the FDA will respond to other experimental LDL lowering agents. Will the results of outcome studies be needed for those drugs as well? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 21, 2014 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Cholesterol medication Vytorin works better than a statin, researchers say
According to researchers, the cholesterol drug Vytorin lowered cholesterol 20 percent further than a statin. Also, new questions about school meals and childhood obesity. Eboni Williams reports on the day's top health stories. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 18, 2014 Category: Consumer Health News Source Type: news
Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk
Title: Cholesterol Drug Vytorin Linked to Reduced Heart Attack RiskCategory: Health NewsCreated: 11/17/2014 12:00:00 AMLast Editorial Review: 11/18/2014 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - November 18, 2014 Category: Cardiology Source Type: news
IMPROVE-IT: Modest Clinical Benefit from Ezetimibe (FREE)
By Larry Husten
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Adding ezetimibe to statin therapy in patients with an acute coronary event is associated with a small reduction in adverse cardiovascular outcomes, according to results of the IMPROVE-IT study presented Monday at the American … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 18, 2014 Category: Primary Care Source Type: news
Study Finds Alternative to Anti-Cholesterol Drug
The finding, which showed that the drug ezetimibe lowers LDL cholesterol, can help millions who cannot tolerate statins or do not respond to them sufficiently. (Source: NYT Health)
Source: NYT Health - November 17, 2014 Category: Consumer Health News Authors: By GINA KOLATA Tags: Heart Zetia (Drug) Cholesterol Vitorin Medicine and Health Statins (Cholesterol-Lowering Drugs) Source Type: news
What I'm Telling Patients About Ezetimibe (Zetia) on Monday What I'm Telling Patients About Ezetimibe (Zetia) on Monday
Dr Melissa Walton-Shirley summarizes the points of IMPROVE-IT for her patients. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2014 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
IMPROVE-IT: 'Modest' Benefit With Ezetimibe in Post-ACS PatientsIMPROVE-IT: 'Modest' Benefit With Ezetimibe in Post-ACS Patients
It's taken 9 years to learn whether or not adding ezetimibe to statins provide any clinical benefit in post-ACS patients. The answer: yes, it does, but the benefit is modest. What this means in the real world will likely be debated for many months to come. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
Surprise! Vytorin Works. Here Are Five Things You Should Know.
For 12 years, there’s been a raging, multibillion-dollar controversy in the giant market for cholesterol-lowering drugs taken by 20 million or more Americans: do one set of pills, Zetia and Vytorin from Merck, actually prevent heart attacks or are the pills, in the memorable words of one top cardiologist, expensive placebos? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Dateline City:
CHICAGO
CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the investigational IMPROVE-IT study met its
primary and all secondary composite efficacy endpoints.
Language:
English
Contact:
MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185
Ticker Slug:
...
Source: Merck.com - Product News - November 17, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
CardioBreak: Energy Drinks, Gene Clues on Ezetimibe
(MedPage Today) -- Recent developments of interest in cardiovascular medicine. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 17, 2014 Category: Urology & Nephrology Source Type: news
IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe
After all the waiting and all the controversy it turned out to be pretty simple. The IMPROVE-IT trial did what it set out to do and reached its primary endpoint. The benefit wasn't very big or impressive but it will be enough to put to rest concerns that ezetimibe might have been an expensive placebo or that LDL might not be a reliable surrogate endpoint. The IMPROVE-IT results will also provide comfort to companies developing the next generation of cholesterol drugs, since their approval may have depended on validation of LDL as a surrogate endpoint. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
AHA: IMPROVE-IT Proves Ezetimibe Benefit (CME/CE)
(MedPage Today) -- Statins are good at reducing cholesterol, but a statin plus ezetimibe is even better. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 17, 2014 Category: Urology & Nephrology Source Type: news
Merck & Co says long-term cholesterol drug study met primary endpoint
Merck said that its long-term Improve-It trial, which was aimed at showing whether its Zetia and Vytorin franchise does more than reduce "bad" cholesterol. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 17, 2014 Category: Pharmaceuticals Source Type: news
Merck says long-term cholesterol drug study met primary endpoint
(Reuters) - Merck & Co said on Monday that its long-term Improve-It trial, which was aimed at showing whether its Zetia and Vytorin franchise does more than reduce "bad" cholesterol, had met its primary endpoint. (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
After Years Under Attack, Merck's Vytorin Proves Effective
Since 2007, the blockbuster cholesterol pills Zetia and Vytorin have been under a cloud as many doctors questioned their effectiveness at preventing heart attacks – and those questions have caused prescriptions of the pills to fall by more than 50%. Today, that cloud lifts. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
